Clinical Trial

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also study how the immune system responds to the study treatment. Pembrolizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1 (PD-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-07-22; most recent amendment 2026-05-13.
Status change: Not Yet Recruiting → Recruiting 2025-12-10
Trial Details
NCT Number NCT07089992
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Sarcoma
Enrollment 32 participants
Start Date 2025-12-04
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-28